AcuteCVDays 2025 - Week 4

Antithrombotic Therapy in patients with PAD

A 68-year-old man with symptomatic lower extremity peripheral artery disease (PAD) and a history of prior femoropopliteal revascularization presents for follow-up. He is currently on aspirin monotherapy. He has hypertension, dyslipidemia, and no history of major bleeding or anticoagulation. According to the 2024 ESC Guidelines, which of the following antithrombotic strategies should be considered to reduce the risk of both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in this patient?

Aspirin monotherapy

Clopidogrel monotherapy

Rivaroxaban (2.5 mg BID) + aspirin

Ticagrelor + aspirin

{"name":"AcuteCVDays 2025 - Week 4", "url":"https://www.quiz-maker.com/Q450P9VR4","txt":"Antithrombotic Therapy in patients with PAD A 68-year-old man with symptomatic lower extremity peripheral artery disease (PAD) and a history of prior femoropopliteal revascularization presents for follow-up. He is currently on aspirin monotherapy. He has hypertension, dyslipidemia, and no history of major bleeding or anticoagulation. According to the 2024 ESC Guidelines, which of the following antithrombotic strategies should be considered to reduce the risk of both major adverse cardiovascular events (MACE) and major adverse limb events (MALE) in this patient? .quiz-container.quiz-embed {padding: 0!important;} BODY .qp_container{padding: 0!important; margin-top:0!important; margin-bottom: 0!important} .qp_b{max-width:100%;} BODY .qp_bo{max-width:100%;} .qp_t{padding-left:0;} qp_i{margin-right: 10px; margin-bottom: 25px;} .qp_a INPUT[type='radio']{margin-right: 10px; margin-bottom: 25px;} @media only screen and (max-width: 480px){.qp_flex.cf2 .qp_flexc{width: 100%;!important;}}","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}